Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Dulaglutide · Trulicity, LY-2189265

Fusion protein · Agonist of GLP-1 receptor (GLP1R) · developed by Eli Lilly And Co

Approved FDA, Sep 2014

LLY Developer

What is Dulaglutide?

Dulaglutide is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous GLP-1. It activates the GLP-1 receptor on pancreatic beta cells, increasing intracellular cAMP and glucose-dependent insulin release, while decreasing glucagon secretion and slowing gastric emptying.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Trulicity, LY-2189265
Drug type: Fusion protein
Targets: GLP-1 receptor (GLP1R)
Mechanism: Agonist of GLP-1 receptor (GLP1R)
Pathways: cAMP signaling, glucose-dependent insulin release, glucagon secretion inhibition
Therapy area: Endocrine
Developer: Eli Lilly And Co (LLY)
FDA status: Approved as Trulicity (September 18, 2014), BLA125469 · FDA label
UNII: WTT295HSY5

✅ FDA-approved uses

Type 2 diabetes mellitus
Reduction of major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors

From the indications section of the FDA label (version of Jun 16, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Diabetes Mellitus, Type 2

Other drugs acting on GLP1R

Orforglipron FDA approved Semaglutide FDA approved Tirzepatide FDA approved Avexitide Phase 3 Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from Eli Lilly And Co

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Dulaglutide

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z